Literature DB >> 9706206

Field study of vaccination of cattle with Brucella abortus strains RB51 and 19 under high and low disease prevalence.

V R Lord1, G G Schurig, J W Cherwonogrodzky, M J Marcano, G E Melendez.   

Abstract

OBJECTIVE: To assess humoral and protective immunity in cattle vaccinated by 12 months with Brucella abortus vaccine strains RB51 and 19 under field conditions of high and low brucellosis prevalence. ANIMALS: 450 seronegative female cattle: 330 three to eight months old (calves), and 120 ten to twelve months old (heifers). PROCEDURES: Ranch A had high prevalence (39%) of brucellosis, and ranch B had low prevalence (2%), as determined by results of conventional serologic testing: agar gel immunodiffusion and the ring test. Seronegative cattle were vaccinated once or twice with 5 x 10(9) colony-forming units of B abortus strain RB51 or once with strain 19. After vaccinating 285 cattle with strain RB51 and 165 with strain 19, 74 (26%) and 30 (18%), respectively, were bred to seropositive bulls, then were kept within the infected herd of origin.
RESULTS: All cattle vaccinated with strain 19 seroconverted 30 days later. All 285 cattle vaccinated with strain RB51 had negative results for all serologic tests, including agar gel immunodiffusion. All RB51-vaccinated cattle that became pregnant had negative results for the ring test and for conventional serologic tests after their first calving.
CONCLUSIONS: Strain RB51 can be used as a live organism vaccine without inducing antibody titers that interfere with serodiagnosis, and induced 100% protection against field strain B abortus-induced abortion in cattle vaccinated at least 1 year before mating to an infected bull. Vaccination with strain 19 under similar conditions was less effective than vaccination with strain RB51.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9706206

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  17 in total

1.  Effect of vaccination with Brucella abortus strain RB51 on heifers and pregnant cattle.

Authors:  F A Uza; L Samartino; G Schurig; A Carrasco; K Nielsen; R F Cabrera; H R Taddeo
Journal:  Vet Res Commun       Date:  2000-04       Impact factor: 2.459

2.  Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge.

Authors:  Xinghong Yang; Beata Clapp; Theresa Thornburg; Carol Hoffman; David W Pascual
Journal:  Vaccine       Date:  2016-09-14       Impact factor: 3.641

3.  Complement fixation test to assess humoral immunity in cattle and sheep vaccinated with Brucella abortus RB51.

Authors:  R Adone; F Ciuchini
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection.

Authors:  P Pasquali; R Adone; L C Gasbarre; C Pistoia; F Ciuchini
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Recombinant Omp2b antigen-based ELISA is an efficient tool for specific serodiagnosis of animal brucellosis.

Authors:  Melody Vatankhah; Nazanin Beheshti; Shiva Mirkalantari; Nima Khoramabadi; Haniyeh Aghababa; Mehdi Mahdavi
Journal:  Braz J Microbiol       Date:  2019-07-27       Impact factor: 2.476

6.  Serological and bacteriological responses of water buffalo (Bubalus bubalis) vaccinated with two doses of Brucella abortus strain RB51 vaccine.

Authors:  Anil Ramnanan; Michael Diptee; Zinora Asgarali; Mervyn Campbell; Abiodun Adewale Adesiyun
Journal:  Trop Anim Health Prod       Date:  2012-10       Impact factor: 1.559

7.  Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308.

Authors:  Paolo Pasquali; Adone Rosanna; Claudia Pistoia; Paola Petrucci; Franco Ciuchini
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

8.  Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation.

Authors:  R Vemulapalli; Y He; L S Buccolo; S M Boyle; N Sriranganathan; G G Schurig
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

9.  Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses.

Authors:  R Vemulapalli; Y He; S M Boyle; N Sriranganathan; G G Schurig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 10.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.